MK-0947
unknown (auto-discovered: neuro-cognition)
Also known as: [¹⁸F]MK-0947
Classification
ResearchCompound
Regulatory Status
investigational; registered trials: NCT07880379 (PHASE1)
Unofficial source
Sources
1
Review
pending review
Overview
Unknown — MK-0947 was found by open discovery on 2026-10-26 and has not been researched yet.
Evidence and limitations
Known
n/a
Unknown
- Mechanism, dosing, safety, interactions and efficacy are unknown until research runs on this auto-discovered draft.
Study details: trial conditions, not guidance
These are the conditions researchers used in a controlled trial with medical supervision. They aren't instructions.
Doses found
Doses as found in each source, with its grade. What was found, not a direction.
Studies, trials and professional sources
n/a
Reddit, Facebook, Instagram, forums and blogs
n/a
Claims and grades
- Not gradedMK-0947 is being studied in a registered trial: MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD) (NCT07880379; PHASE1; RECRUITING; sponsor XingImaging, LLC; intervention "[¹⁸F]MK-0947" (DRUG)).
Sources (1)
- MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD) (opens in a new tab) · ClinicalTrials.gov · trial-registry · 2026-10-19
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw